Letters to the Editor
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
https://doi.org/10.4084/MJHID.2023.021

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: February 28, 2023
1620
Views
945
Downloads
648
HTML
Chronic ITP, ITP, thrombopoietin, new agents, New Drugs, Refractory ITP

Authors

Monica Carpenedo
mnc.carpenedo@gmail.com
Dr
A.O San Gerardo di Monza e Università di Milano Bicocca, Hematology and Transplant Unit via Pergolesi 33. Monza, IT 20900, Italy.
Dr
A.O San Gerardo di Monza e Università di Milano Bicocca, Hematology and Transplant Unit via Pergolesi 33. Monza, IT 20900, Italy.
Dr
A.O San Gerardo di Monza e Università di Milano Bicocca, Hematology and Transplant Unit via Pergolesi 33. Monza, IT 20900, Italy.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
REFERENCES:
Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012;38:454–62
Audia S and Bonnotte B. Emerging therapies in Immune Thrombocytopenia. J. Clin. Med. 2021, 10, 1004
Miltiadous O, Hou M, Bussel JB, Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020;135(7):472-490
Cooper N, Kruse A, Kruse C, Watson S, Morgan M et al Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hem 2021 Feb 1;96(2):199-207.doi: 10.1002/ajh.26036
Ulrichts P et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans J Clin Invest 2018 Oct 1;128(10):4372-4386
Broome C, McDonald V, Miyakawa Y, Carpenedo, M et al. Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary ITP: Results of ADVANCE IV, a Phase 3, Multicenter, Double blinded, Placebo-controlled, Randomized Clinical Trial , 64th ASH Annual Meeting, New Orleans, 10-13th December 2022
Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104:1112–23.
Schifferli A et al. Immunomodulation in Primary immune Trhombocytopenia: a possible role of the Fc fragment of romiplostim? ) Front Imm 2019; 10: 1196
De Groot A et al. Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction. Sci Rep 2019 Nov 6;9(1):16103
Blumberg RS, Lillicrap D, IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. (2018) 131:2205–14

How to Cite



“Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists” (2023) Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023021. doi:10.4084/MJHID.2023.021.
Copyright (c) 2023 Monica Carpenedo, Dr, Dr, Dr Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.